Join BJS Academy
BJS Academy>Randomized clinical ...>Ribociclib plus endo...
Normal View Dyslexic View

Ribociclib plus endocrine therapy in early breast cancer.

21 June 2024
Randomized clinical trials Breast
Slamon D, Lipatov O, Nowecki Z, McAndrew N, Ika-Budny BK, Stroyakovskiy D et al.

N Engl J Med 2024; 390: 1080-1091.

The addition of ribociclib to standard aromatase inhibitor treatment for women with hormone receptor positive, HER2-negative early breast cancer significantly improved 3-year disease-free survival from 87.1 to 90.4 per cent (P=0.003) in this large international study.

Comment: More information towards optimized adjuvant therapy.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct007
Randomized clinical trials
Randomized clinical trials
Breast
Ribociclib plus endocrine therapy in early breast cancer.
Slamon D, Lipatov O, Nowecki Z, McAndrew N, Ika-Budny BK, Stroyakovskiy D et al.
21062024
N Engl J Med 2024; 390: 1080-1091.
The addition of ribociclib to standard aromatase inhibitor treatment for women with hormone receptor positive, HER2-negative early breast cancer significantly improved 3-year disease-free survival from 87.1 to 90.4 per cent (P=0.003) in this large international study.
Comment: More information towards optimized adjuvant therapy.
Published on: 21 June 2024
Article ID: rct007

Related articles

Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.

Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM et al.

16 August 2024

21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF et al.
N Engl J Med 2021; 385: 2336-2347

1 January 2022

Event-free survival with pembrolizumab in early triple-negative breast cancer.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S et al, for the KEYNOTE-522 Investigators.
N Engl J Med 2022; 386: 556-567.

1 March 2022
Home
  • Normal view
  • Dyslexic view
Info
Copied!